Capital Fund Management S.A. Acquires New Holdings in Merus (NASDAQ:MRUS)

Capital Fund Management S.A. acquired a new position in shares of Merus (NASDAQ:MRUS - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 10,158 shares of the biotechnology company's stock, valued at approximately $427,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. HighTower Advisors LLC purchased a new stake in Merus during the third quarter valued at $358,000. KBC Group NV raised its position in shares of Merus by 4,583.6% during the 4th quarter. KBC Group NV now owns 57,234 shares of the biotechnology company's stock valued at $2,407,000 after buying an additional 56,012 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in shares of Merus by 29.0% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 48,268 shares of the biotechnology company's stock valued at $2,030,000 after acquiring an additional 10,842 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Merus in the 4th quarter valued at about $347,000. Finally, Franklin Resources Inc. grew its position in Merus by 7.1% in the third quarter. Franklin Resources Inc. now owns 2,256,504 shares of the biotechnology company's stock worth $117,722,000 after acquiring an additional 150,341 shares in the last quarter. 96.14% of the stock is currently owned by institutional investors.

Merus Trading Down 0.0 %

Shares of Merus stock traded down $0.02 on Tuesday, hitting $43.21. 550,528 shares of the company traded hands, compared to its average volume of 716,047. Merus has a 52 week low of $33.19 and a 52 week high of $61.61. The company has a market cap of $2.99 billion, a PE ratio of -10.94 and a beta of 1.02. The stock's 50 day moving average price is $43.94 and its 200-day moving average price is $44.92.

Merus (NASDAQ:MRUS - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $9.14 million during the quarter, compared to analyst estimates of $10.57 million. As a group, research analysts anticipate that Merus will post -3.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on MRUS. Guggenheim reaffirmed a "buy" rating and issued a $109.00 price objective on shares of Merus in a research note on Friday, March 28th. Wells Fargo & Company assumed coverage on Merus in a research report on Friday, February 7th. They issued an "overweight" rating and a $91.00 price target for the company. William Blair reiterated an "outperform" rating on shares of Merus in a research report on Friday, February 28th. Piper Sandler started coverage on shares of Merus in a report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $85.00 price target on shares of Merus in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Merus currently has an average rating of "Buy" and an average price target of $85.31.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.